B cells RNA silencing guide

B cells present unique biological barriers that cause conventional transfection to fail or create experimental artifacts:

Suspension cell biology and endosomal escape

B cells grow in suspension, unlike adherent fibroblasts or epithelial cells. Lipofection relies on endocytic uptake of lipoplexes and on their release from the endosome, so the efficiency reported for a primary human B cell is a property of the reagent and the cargo rather than of the cell. Both have to be established for the cell type and the readout in hand, and a labelled control shows what fraction of the culture took up anything at all.

High impact

Transfection-induced BCR activation

Cationic lipids and electroporation can trigger B cell activation through stress response pathways. Lipoplexes may stimulate BCR-independent calcium flux, activate downstream signaling (SYK, BTK, PLCγ2), and induce activation markers (CD69, CD86, HLA-DR upregulation) within hours. This creates experimental artifacts: in a study of naive B cell biology, BCR signal thresholds or anergy and tolerance, an activation the delivery step caused can be read as the target's. A differentiation readout, by contrast, survives the delivery step: in primary naive human B cells nucleofected with a non-targeting siRNA and then cultured for seven days with CD40 ligand, IL-21, anti-IgM and CpG, plasmablast generation was unchanged. The same work had to raise its cells per well to recover plasmablast generation after a mock nucleofection, so the risk to a differentiation experiment is under-recovery rather than premature differentiation, and the plasmablast gate is read against a mock-nucleofected control at the density the culture was optimized for.

High impact

Electroporation toxicity and membrane damage

The viability cost of electroporating B cells depends on what is delivered: across studies, the loss is greater with plasmid DNA than with a small oligonucleotide or a ribonucleoprotein. Read it with Trypan blue or 7-AAD exclusion within 24h post-electroporation, for the cargo in hand rather than from a figure measured with another. Where the pulse does cost the culture, the surviving B cells can show compromised membrane integrity, with calcium dysregulation, which matters most in a BCR signaling study, and altered responsiveness to the B cell activators anti-IgM, CD40L and CpG; the lipid rafts where BCR signaling complexes assemble are a candidate for it. So read the calcium response and the activator response against a mock-electroporated control before reading a signaling, calcium flux or gene induction result out of electroporated cells.

High impact

Endosomal escape and lysosomal degradation

B cells process internalized antigen through the endosomal-lysosomal system (mature endosomes pH 5.5-6.0, lysosomes pH 4.5-5.0), which carries nucleases and proteases. A lipoplex that is endocytosed and not released reaches those compartments, so endosomal escape sets how much of the cargo acts, and how much escapes depends on the reagent. The "endosomal escape problem" is a property of the reagent and is measured with a labelled cargo rather than assumed.

Medium impact

B cell line limitations and non-representative biology

Commonly used B cell lines (Raji, Daudi, BJAB) are derived from Burkitt lymphoma and carry MYC translocations, constitutive BCR signaling mutations, and altered cell cycle checkpoints. While these lines are more transfectable than primary B cells, they do not represent normal B cell biology. Raji cells have EBV infection, Daudi cells lack MHC Class I expression, and BJAB cells have disrupted TP53. Findings in these lines may not translate to primary human B cells, germinal center B cells, or other B cell lymphoma subtypes (DLBCL, mantle cell lymphoma, marginal zone lymphoma).

Medium impact

Activation state and the transfection window

B cells exist in multiple developmental and activation states: naive B cells (resting, quiescent), germinal center B cells (rapidly dividing, undergoing somatic hypermutation and class switching), memory B cells (resting, antigen-experienced), plasmablasts (differentiating), and plasma cells (terminally differentiated, non-dividing antibody factories). What governs electroporation is time in activating culture rather than the subset: freshly isolated B cells show no expression of an electroporated reporter, whatever subset they belong to, and naive B cells reach the same efficiency as the other subsets after several days of CD40 ligand culture. So a differentiation trajectory cannot be read from electroporated cells without activating them first, and that activation is itself the perturbation the experiment is trying to avoid.

High impact

Method comparison

Why AUMsilence™ sdASOs™ suit B cells

Key benefits

• Viability for extended assays. No transfection reagent is added and no pulse is applied, so the delivery step brings no membrane damage. Read viability against a non-targeting control before a BCR signaling time course, long-term antibody production (7-14 days), a class switch recombination study or a B-T cell co-culture.
• Enables BCR signaling pathway dissection. Knockdown BCR components (CD79A, CD79B), kinases (BTK, SYK, LYN), or effectors (PLCγ2, BLNK). Measure calcium flux, phospho-signaling, activation marker upregulation, proliferation.
• B cell lymphoma biology studies. Knockdown lymphoma oncogenes (MYC, BCL6, BCL2, PAX5) in B cell lines (Raji, Daudi) or primary lymphoma cells. Measure proliferation, apoptosis, BCR signaling addiction. Model lymphoma dependencies without long-term CRISPR knockout effects.
• Class switching and antibody production. Knockdown AID (AICDA) to block class switch recombination, BLIMP1 to prevent plasma cell differentiation, XBP1 to impair antibody secretion. Dissect antibody diversification mechanisms (somatic hypermutation, CSR) and plasma cell biology.
• CAR-T target validation. Knockdown CD19 or CD20 in B cell lymphoma lines to model antigen loss escape. Test if lymphoma cells survive without CD19/CD20 (predict CAR-T resistance). Validate alternative targets (CD22, CD79A, CD79B).
• Rapid timeline for target validation. Test gene function in 3-5 days: isolate B cells, add ASO, validate knockdown, perform functional assays. No viral vector cloning, no electroporation optimization. Accelerates hypothesis testing in B cell biology.

Cell types and applications

• Primary human B cells (CD19+ from peripheral blood, tonsils, lymph nodes)
• B cell lines (Raji, Daudi, BJAB, SU-DHL-4, JeKo-1)
• BCR signaling pathway dissection (BTK, SYK, PLCγ2, CD79A/B)
• B cell lymphoma biology (DLBCL, Burkitt, follicular lymphoma, CLL, mantle cell)
• Oncogene studies (MYC, BCL6, BCL2, PAX5, IRF4)
• Class switch recombination and somatic hypermutation (AID/AICDA)
• Plasma cell differentiation (BLIMP1, IRF4, XBP1)
• Antibody production and optimization
• B cell survival pathways (BAFF-R, CD19, CD40, BCL2)
• Autoimmune disease mechanisms (regulatory B cells, IL-10, TGF-β)
• CAR-T target validation (CD19, CD20, CD22 escape)
• Emerging CAR-B cell engineering (antibody-secreting engineered B cells)

• AUMsilence™ sdASO™

Alternative products

• AUMsilence™ toASO™ When to use: Economy option for B cell line studies (Raji, Daudi, BJAB) and high-throughput screening. Recommended for non-critical optimization experiments before moving to primary B cells with AUMsilence sdASO.
• AUMantagomir™ sdASO™ When to use: For microRNA inhibition in B cells. Recommended for studying miR-155-5p (germinal center B cell proliferation) and miR-150-5p (B cell development). miR-181 names a family, miR-181a to miR-181d, so an inhibitor is made against one member and one arm.
• Consult our scientists When to use: For novel B cell targets or multi-gene lymphoma panels. AUM scientists design and validate 3-5 ASO candidates per target, optimized for human sequences.

Optimized protocols for primary human B cells, B cell lines (Raji, Daudi, BJAB), and B cell differentiation studies. No transfection reagents required.

Quick start protocol (all B cell types)

1. 01Culture B cells at 0.5-1 × 10⁶ cells/mL in appropriate medium (RPMI + 10% FBS for primary, RPMI + 20% FBS for Raji/Daudi)
2. 02Add AUMsilence™ sdASO™ directly to culture medium at 10 μM final concentration (no transfection reagent required)
3. 03Incubate 48-72 hours at 37°C, 5% CO₂
4. 04Validate knockdown by qRT-PCR (48h after treatment) and flow cytometry or Western blot (72h after treatment)
5. 05Perform functional assays: BCR signaling (calcium flux), antibody production (ELISA), proliferation (CFSE), differentiation (CD27, CD38, CD138)

Cell-type-specific protocols

Primary human B cells (CD19+ from PBMCs)

Freshly isolated or cryopreserved peripheral blood B cells

1. 01

   Step 1: B cell isolation from PBMCs

   Isolate B cells from PBMCs using CD19 magnetic bead positive selection. Negative selection alternative: deplete T cells (CD3), monocytes (CD14), and NK cells (CD56). CD19+ selection yields 95-98% purity. The B cell share of a PBMC preparation varies between donors, so measure it on the CD19 gate before selection rather than planning from a typical figure. Can also isolate from tonsils (higher yield, more germinal center B cells) or lymph nodes.

   Materials: RPMI-1640 + 10% FBS + 1% Pen/Strep, CD19 magnetic beads

   Note: Primary B cells are fragile; handle gently. Freshly isolated B cells are quiescent (naive) and require activation for proliferation studies. Do not use T cell media (RPMI works for both).

   Timing: Day 0

2. 02

   Step 2: Primary B cell culture (unstimulated or activated)

   Seed freshly isolated B cells at 0.5-1 × 10⁶ cells/mL in complete RPMI. For unstimulated (naive) B cells: culture without additional stimulation (short-term studies, 2-4 days). For activated B cells: add B cell activators at Day 0: (1) anti-IgM F(ab')₂ (10 μg/mL, BCR crosslinking), (2) CD40L (1 μg/mL, co-stimulation), (3) CpG ODN 2006 (2.5 μM, TLR9 agonist), (4) BAFF and APRIL (50-100 ng/mL, survival signals). Activation induces proliferation (measure by CFSE dilution) and upregulation of activation markers (CD69, CD86, CD25).

   Materials: RPMI + FBS, anti-IgM, CD40L, CpG, BAFF, APRIL

   Note: Naive B cells survive 2-4 days without activation and undergo apoptosis without survival signals. Activated B cells proliferate and survive 7-14 days. Plan ASO treatment timing based on activation state.

   Timing: Day 0-2

3. 03

   Step 3: AUMsilence sdASO treatment of primary B cells

   At Day 1-2 (24-48h post-isolation, with or without activation), add AUMsilence sdASO directly to culture at 10 μM. For 500 μL culture (24-well), add 5 μL of 1 mM AUMsilence sdASO stock. No media change required. AUMsilence sdASOs bind proteins on the cell surface and are taken up by endocytosis, followed by intracellular trafficking; a small fraction escapes endosomes to reach the cytosol and nucleus where target engagement occurs via RNase H1.

   Materials: AUMsilence sdASO (1 mM stock in nuclease-free water)

   Note: The recommended working range is 5-20 μM, with a starting concentration of 10 μM. Results vary by target gene stability, expression level, and cell division rate.

   Timing: Day 1-2

4. 04

   Step 4: Incubation and monitoring

   Incubate 48-72h at 37°C, 5% CO₂. Monitor cell density and viability daily. B cells remain in suspension. Do not change medium unless a specific assay requires it (loss of secreted factors).

   Materials: Humidified CO₂ incubator

   Note: mRNA knockdown is typically achieved 24-72 hours after treatment. Functional assays typically at 72h-96h post-ASO. For proliferation studies, activated B cells divide every 18-24h.

   Timing: Days 1-4

5. 05

   Step 5: Validation and functional assays

   At 48h after treatment: qRT-PCR for mRNA knockdown, expect 70-95% knockdown. At 72h: flow cytometry for surface markers (CD19, CD20, BAFF-R, BCR components) or intracellular proteins (BCL6, PAX5, BLIMP1, IRF4). Functional assays at 72-96h: (1) BCR signaling: anti-IgM stimulation, measure calcium flux (Indo-1 or Fluo-4 by flow), phospho-SYK/BTK/PLCγ2 by phospho-flow, (2) Proliferation: CFSE dilution after CD40L+anti-IgM stimulation, (3) Antibody production: culture with activators 5-7 days, measure IgM/IgG/IgA in supernatants by ELISA, (4) Differentiation: plasma cell markers (CD27high CD38high CD138+), measure by flow.

   Materials: Flow antibodies, calcium indicators, ELISA kits, CFSE

   Note: Calcium flux is gold standard for BCR function. Read it in AUMsilence sdASO-treated cells against the untreated control; a change is expected where the target is in the calcium pathway.

   Timing: Days 3-7

Raji cells (Burkitt lymphoma B cell line)

EBV-positive Burkitt lymphoma cell line, most common B cell research model

1. 01

   Step 1: Raji cell culture

   Culture Raji cells in RPMI-1640 + 10-20% FBS. Cells grow in suspension, doubling time 20-24h. Maintain at 2-8 × 10⁵ cells/mL. Split 1:3 to 1:5 every 2-3 days. Raji cells are Burkitt lymphoma line with MYC translocation t(8;14), constitutive BCR signaling, and EBV positivity (express EBV latency proteins EBNA1, LMP1, LMP2).

   Materials: RPMI-1640 + 10-20% FBS

   Note: Raji cells are hardy B cell line and easier to culture than primary B cells. Used extensively for BCR signaling studies, lymphoma biology, and CAR-T target validation (CD19, CD20).

   Timing: Maintain stock culture

2. 02

   Step 2: AUMsilence sdASO treatment of Raji cells

   Seed Raji at 3-5 × 10⁵ cells/mL in fresh medium 24h before ASO treatment. Add AUMsilence sdASO at 10 μM final concentration. AUMsilence sdASOs are taken up by endocytosis.

   Materials: AUMsilence sdASO

   Note: Raji cells useful for screening applications, BCR signaling pathway dissection, lymphoma oncogene studies (BCL6, MYC, BCL2). Validate key findings in primary B cells.

   Timing: Day 0-3

3. 03

   Step 3: Lymphoma biology applications

   Raji is Burkitt lymphoma model for studying MYC-driven biology: (1) MYC knockdown reduces proliferation 60-80% and induces apoptosis (measure annexin V/7-AAD), (2) BCL6 knockdown (DLBCL transcriptional repressor also expressed in Burkitt), (3) BCR signaling addiction: knockdown CD79A, CD79B, SYK, or BTK and measure apoptosis (Burkitt cells depend on tonic BCR signaling), (4) CD19/CD20 knockdown for CAR-T target validation (measure surface receptor loss, predict antigen escape).

   Materials: Standard validation reagents, apoptosis assays

   Note: Raji represents Burkitt biology (MYC-driven) but not other B cell lymphomas (DLBCL, follicular). Use appropriate cell lines for specific lymphoma subtypes: SU-DHL-4 (DLBCL), JeKo-1 (mantle cell), and WSU-DLCL2 (activated B-cell DLBCL).

   Timing: Days 2-5

Daudi cells (Burkitt lymphoma, MHC class I-deficient)

Burkitt lymphoma line lacking MHC Class I (B2M mutation)

1. 01

   Step 1: Daudi cell culture and properties

   Culture Daudi in RPMI-1640 + 10-20% FBS. Suspension culture, doubling time 24-30h. Maintain at 2-8 × 10⁵ cells/mL. Daudi is Burkitt lymphoma (like Raji) but with B2M (beta-2 microglobulin) mutation and lacks surface MHC Class I (HLA-A, -B, -C). This makes Daudi sensitive to NK cell killing (loss of "self" recognition) but resistant to CD8+ T cell recognition.

   Materials: RPMI-1640 + FBS

   Note: Daudi useful for: NK cell target studies (MHC Class I-negative), B cell intrinsic biology (without MHC Class I signaling confounds), BCR signaling, apoptosis pathways.

   Timing: Maintain stock culture

2. 02

   Step 2: AUMsilence sdASO in Daudi cells

   Add AUMsilence sdASO at 10 μM final concentration to Daudi cultures. Use for studies where MHC Class I absence is advantageous: BCR signaling without T cell interactions, B cell-intrinsic apoptosis (no CTL confound), NK-B cell interactions (Daudi is NK cell target).

   Materials: AUMsilence sdASO

   Note: Daudi vs. Raji selection: use Daudi if studying B cell-intrinsic pathways without MHC Class I/T cell confounds. Use Raji for more general Burkitt lymphoma biology.

   Timing: Day 0-3

Plasma cell differentiation studies

B cell to plasma cell differentiation and antibody production

1. 01

   Step 1: Inducing plasma cell differentiation from primary B cells

   Activate naive B cells with CD40L (1 μg/mL) + IL-21 (50 ng/mL) + IL-4 (10 ng/mL) for 5-7 days to induce plasmablast/plasma cell differentiation. Alternatively: CpG (2.5 μM) + IL-21 + IL-2 (20 U/mL) for rapid differentiation (3-5 days). Differentiation markers: CD27 (memory B cell/plasmablast), CD38 (plasma cell), CD138/syndecan-1 (mature plasma cell), loss of CD20, upregulation of BLIMP1 (master plasma cell transcription factor), IRF4, XBP1 (unfolded protein response factor required for antibody secretion).

   Materials: CD40L, IL-21, IL-4, CpG, IL-2

   Note: Plasma cell differentiation is terminal: cells stop dividing and massively expand ER for high-rate antibody production. Timing critical for ASO treatment depending on experimental question.

   Timing: Day 0-7

2. 02

   Step 2: ASO treatment for differentiation pathway dissection

   Two experimental strategies: (1) Pre-differentiation knockdown: add AUMsilence sdASO at Day 0 (before differentiation stimuli), test whether the target gene is required for differentiation (e.g., BLIMP1, IRF4 knockdown prevents plasma cell formation), (2) Post-differentiation knockdown: differentiate for 3-4 days, add AUMsilence sdASO, test function in established plasmablasts/plasma cells (e.g., XBP1 knockdown in differentiated cells reduces antibody secretion without affecting differentiation per se).

   Materials: AUMsilence sdASO targeting BLIMP1, IRF4, XBP1, PAX5 (represses plasma cell genes)

   Note: BLIMP1 (encoded by PRDM1) is master regulator; knockdown blocks plasma cell differentiation. PAX5 maintains B cell identity; knockdown allows plasma cell differentiation. IRF4 required for plasma cell maturation. XBP1 required for ER expansion and antibody secretion.

   Timing: Day 0 or Day 3-4

3. 03

   Step 3: Antibody production measurement

   At Day 5-7 post-differentiation, measure secreted antibodies in culture supernatants by ELISA: total IgM, IgG, IgA (isotype-specific ELISA). For class switching studies (IgM → IgG or IgA), measure class switch recombination by: (1) flow cytometry for surface IgG+ or IgA+ cells, (2) qRT-PCR for germline transcripts (Iγ, Iα; precede switch recombination), (3) chromosome conformation capture (3C) to detect recombined heavy chain loci.

   Materials: ELISA kits (IgM, IgG, IgA), flow antibodies (anti-IgG, anti-IgA)

   Note: Class switch recombination (CSR) requires AID (AICDA, activation-induced cytidine deaminase). AID knockdown prevents class switching, and cells remain IgM+. CSR induced by CD40L + IL-4 (IgG1/IgE), CD40L + TGF-β (IgA), or CD40L + IFN-γ (IgG2a in mice).

   Timing: Days 5-7

BCR signaling and calcium flux studies

Dissect BCR signal transduction pathways

1. 01

   Step 1: BCR signaling component knockdown

   Treat primary B cells or Raji cells with AUMsilence sdASO targeting BCR signaling components: (1) Proximal: CD79A (Igα) and CD79B (Igβ); ITAM-containing signaling subunits, (2) Kinases: LYN, SYK, BTK, (3) Adapters and effectors: BLNK (SLP-65), PLCγ2, VAV1. Allow 24-72 hours for knockdown. Validate by Western blot (phospho-SYK Tyr525/526, phospho-BTK Tyr223, phospho-PLCγ2 Tyr1217).

   Materials: AUMsilence sdASO targeting BCR signaling genes

   Note: BTK (Bruton's tyrosine kinase) is clinical target. Ibrutinib (BTK inhibitor) approved for CLL, mantle cell lymphoma, and Waldenstrom's. Genetic knockdown validates BTK requirement before drug studies.

   Timing: Day 0-3

2. 02

   Step 2: BCR stimulation and calcium flux measurement

   At 72h post-ASO, stimulate BCR and measure calcium flux. Load B cells with calcium indicator (Fluo-4 AM or Indo-1 AM, 30 min at 37°C), wash, baseline 30-60 sec, then add anti-IgM F(ab')₂ (10 μg/mL, BCR crosslinking). Measure calcium flux by flow cytometry (kinetic measurement, Indo-1 ratiometric) or plate reader (population average). BCR stimulation triggers rapid calcium release from ER (within 10-30 sec) followed by sustained calcium influx (store-operated calcium entry, SOCE).

   Materials: Fluo-4 AM, Indo-1 AM, anti-IgM F(ab')₂, flow cytometer with kinetic capability

   Note: Calcium flux is hallmark of BCR activation. BTK or PLCγ2 knockdown abolishes calcium response. SYK knockdown severely reduces calcium flux. CD79A/B knockdown (BCR complex itself) eliminates response. Read the calcium response against a non-targeting control, which is what makes the dissection of signaling requirements authentic.

   Timing: Day 3

3. 03

   Step 3: Downstream signaling and gene induction

   After BCR stimulation (anti-IgM, 6-24h), measure downstream events: (1) Phospho-flow: intracellular staining for phospho-ERK1/2 (Thr202/Tyr204), phospho-AKT (Ser473), and phospho-S6 (Ser235/236); measure by flow cytometry in fixed/permeabilized cells, (2) Activation markers: CD69, CD86, CD25 surface upregulation (flow cytometry, 18-24h post-BCR stimulation), (3) Proliferation: CFSE dilution (requires CD40L co-stimulation for sustained proliferation, BCR alone gives limited division).

   Materials: Phospho-flow antibodies, activation marker antibodies, CFSE

   Note: BCR signaling activates multiple pathways: calcium-NFAT (transcription), NF-κB (survival and activation), PI3K-AKT (metabolism and survival), and MAPK-ERK (proliferation). Knockdown of pathway-specific components dissects signaling logic.

   Timing: Days 3-4

Essential controls for B cell experiments

• Untreated B cells: Baseline BCR responsiveness, surface marker expression, antibody production
  Culture identically without ASO. Critical for reading whether the ASO changes the activation state.
• Non-targeting control ASO: Control for non-specific ASO effects on B cell biology
  Use AUM non-targeting control at 10 μM. Verifies phenotypic changes are target-specific. Critical for BCR signaling studies (ensure no non-specific calcium flux alterations).
• Positive control for BCR signaling: Validate BCR activation capacity
  Stimulate with anti-IgM F(ab')₂ (10 μg/mL) + CD40L (1 μg/mL) for activation. Measure calcium flux, CD69/CD86 upregulation, and proliferation. Confirms the B cells are functionally competent.
• Activation state monitoring: Ensure ASO does not induce unwanted activation
  Measure CD69, CD86, HLA-DR by flow cytometry at 24-48h post-ASO. Compare untreated, non-targeting control, experimental ASO, and read the three against each other.

Optimization strategies for B cell applications

Troubleshooting

Low knockdown efficiency (<50% in primary B cells)

• Verify B cell purity (CD19+CD3-) and viability (>90%) before treatment
• Increase the ASO concentration within the recommended range
• Test positive control (GAPDH or ACTB knockdown) to verify ASO activity
• Ensure cells not undergoing apoptosis (primary B cells die rapidly without survival signals; add BAFF, APRIL, or CD40L)
• Try different donor PBMC preparation
• Design alternative ASO targeting different region of transcript

Unwanted B cell activation (CD69, CD86 upregulation)

• Measure activation markers (CD69, CD86, HLA-DR) in untreated, non-targeting control ASO, and experimental ASO groups
• If activation in both ASO groups: endotoxin or TLR9 issue. Use fresh ASO, verify <0.1 EU/mL endotoxin, reduce the concentration within the recommended range
• If activation only in experimental ASO: expected if targeting negative regulators (e.g., CD22, FcγRIIB). Document as on-target effect
• Include calcium flux assay: non-specific activation shows calcium flux without BCR stimulation

Rapid B cell death or loss of viability

• Add survival signals to primary B cell cultures: BAFF (50-100 ng/mL), APRIL (50-100 ng/mL), or low-level CD40L (0.5 μg/mL)
• Reduce the ASO concentration within the recommended range
• If targeting survival genes (CD19, BAFF-R, BCL2), some death expected. Validate by including viability dye in all assays
• Check culture density: B cells at <2 × 10⁵/mL may die from low paracrine support. Maintain at 5-10 × 10⁵/mL.

No effect on BCR signaling despite knockdown

• Verify protein knockdown by Western blot or flow cytometry (not mRNA alone by qRT-PCR)
• Extend incubation to 96h for stable proteins
• Test positive control: BTK or SYK knockdown abolishes calcium flux (well-validated)
• Consider dual knockdown if pathway redundant (e.g., LYN + FYN both contribute to BCR signaling)
• Use sensitive calcium flux assay (flow cytometry-based, single-cell resolution) rather than population average

High donor-to-donor variability (primary B cells)

• Standardize B cell isolation (same magnetic bead kit, same protocol)
• Phenotype B cells before ASO treatment: naive (IgD+ CD27-), memory (IgD- CD27+), and transitional (CD24high CD38high). Subset distribution affects responses
• Use n≥3 donors for statistical power
• For initial optimization, use B cell lines (Raji, Daudi) for consistency, then validate in 2-3 primary donor preparations

Class switch recombination not occurring despite differentiation stimuli

• Verify AID expression by qRT-PCR (should be highly upregulated 24-48h after CD40L + IL-4 stimulation)
• Confirm CD40L stimulation (1 μg/mL) + cytokine (IL-4 10-20 ng/mL for IgG1)
• Measure proliferation (CFSE dilution); class switching occurs during cell division
• Positive control: CpG + IL-21, which induces CSR
• Measure germline transcripts (Iγ, Iα by qRT-PCR); induced before switch recombination, confirms signaling intact

Quantitative RT-PCR (qRT-PCR)

Flow cytometry (surface and intracellular proteins)

Calcium flux assay (BCR signaling)

Phospho-flow cytometry

Antibody production (ELISA)

Proliferation assays (CFSE dilution)

Critical controls for B cell validation

• Untreated B cells: Baseline BCR signaling, surface marker expression, proliferation, antibody production
  Culture identically without ASO. Essential for reading whether the ASO changes B cell function or the activation state.
• Non-targeting control ASO: Control for non-specific ASO effects on B cell biology
  Use AUM non-targeting control at 10 μM (match experimental ASO concentration and timing). Verifies phenotypic changes are target-specific, not ASO-related. Critical for BCR signaling studies.
• Positive control for BCR activation: Validate B cells are functionally competent
  Stimulate with anti-IgM F(ab')₂ (10 μg/mL) + CD40L (1 μg/mL) for activation. Measure calcium flux, CD69/CD86 upregulation, and proliferation. If positive control fails, B cells are not functional (isolation or culture issue).
• Activation state monitoring: Ensure ASO does not induce unwanted B cell activation
  Measure CD69, CD86, HLA-DR by flow cytometry at 24-48h post-ASO. Compare untreated, non-targeting control, and experimental ASO, and read the three against each other; activation is expected where the target is a negative regulator (CD22, FcγRIIB).
• Differentiation state tracking: For plasma cell studies, track differentiation progression
  Measure CD27, CD38, CD138 (plasma cell markers), BLIMP1, IRF4 (intracellular transcription factors). Document differentiation kinetics: Day 0 (naive), Day 3 (activated), Day 5 (plasmablasts), Day 7 (early plasma cells).

Best practices

• Use biological triplicates (n=3 independent experiments) with different donor PBMC preparations for primary B cells
• Validate knockdown at both mRNA (qRT-PCR, 48h after treatment) and protein (flow/Western, 72h) levels
• For BCR signaling studies, include calcium flux assay (gold standard for BCR function)
• Monitor activation state (CD69, CD86) to ensure no artifacts from ASO treatment
• For differentiation studies, track markers (CD27, CD38, CD138) at multiple timepoints
• Include survival signals (BAFF, APRIL, or CD40L) for primary B cell cultures to prevent apoptosis
• Report viability, activation state, and differentiation state in all publications